Quarterly report pursuant to Section 13 or 15(d)

Research and Development Agreements - Schedule of Impact of Adoption on Condensed Consolidated Statement of Operations and Comprehensive (Detail)

v3.10.0.1
Research and Development Agreements - Schedule of Impact of Adoption on Condensed Consolidated Statement of Operations and Comprehensive (Detail) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Revenue Recognition [Line Items]        
Research and development revenue $ 944 $ 0 $ 1,175 $ 1,760
Total revenue 1,367 42 1,849 1,927
Net loss $ 9,695 $ 4,064 $ 18,409 $ 5,258
Basic and diluted $ 0.36 $ 20.76 $ 0.68 $ 28.32
ASC 2014-09 | Effect of Adoption of ASC 606        
Revenue Recognition [Line Items]        
Research and development revenue $ (11)   $ (79)  
Total revenue (11)   (79)  
Net loss $ 11   $ 79  
Basic and diluted $ (0.00)   $ (0.00)  
ASC 2014-09 | Balance without Adoption of ASC 606        
Revenue Recognition [Line Items]        
Research and development revenue $ 933   $ 1,096  
Total revenue 1,356   1,770  
Net loss $ 9,706   $ 18,488  
Basic and diluted $ 0.36   $ 0.68